Year |
Citation |
Score |
2022 |
François-Moutal L, Scott DD, Ambrose AJ, Zerio CJ, Rodriguez-Sanchez M, Dissanayake K, May DG, Carlson JM, Barbieri E, Moutal A, Roux KJ, Shorter J, Khanna R, Barmada SJ, McGurk L, et al. Heat shock protein Grp78/BiP/HspA5 binds directly to TDP-43 and mitigates toxicity associated with disease pathology. Scientific Reports. 12: 8140. PMID 35581326 DOI: 10.1038/s41598-022-12191-8 |
0.504 |
|
2022 |
Mollasalehi N, Francois-Moutal L, Porciani D, Burke DH, Khanna M. Aptamers Targeting Hallmark Proteins of Neurodegeneration. Nucleic Acid Therapeutics. PMID 35452303 DOI: 10.1089/nat.2021.0091 |
0.765 |
|
2021 |
Cai S, Moutal A, Yu J, Chew LA, Isensee J, Chawla R, Gomez K, Luo S, Zhou Y, Chefdeville A, Madura C, Perez-Miller S, Bellampalli SS, Dorame A, Scott DD, et al. Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Science Translational Medicine. 13: eabh1314. PMID 34757807 DOI: 10.1126/scitranslmed.abh1314 |
0.688 |
|
2021 |
Francois-Moutal L, Scott DD, Khanna M. Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape. Rsc Chemical Biology. 2: 1158-1166. PMID 34458829 DOI: 10.1039/d1cb00110h |
0.721 |
|
2021 |
François-Moutal L, Miranda VG, Mollasalehi N, Gokhale V, Khanna M. Targeting of the Long Noncoding RNA MALAT1. Acs Medicinal Chemistry Letters. 12: 915-921. PMID 34141069 DOI: 10.1021/acsmedchemlett.1c00060 |
0.763 |
|
2020 |
Mollasalehi N, Francois-Moutal L, Scott DD, Tello JA, Williams H, Mahoney B, Carlson JM, Dong Y, Li X, Miranda VG, Gokhale V, Wang W, Barmada SJ, Khanna M. An Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 Yields Neuroprotective Properties. Acs Chemical Biology. PMID 33044808 DOI: 10.1021/acschembio.0c00494 |
0.756 |
|
2020 |
François-Moutal L, Perez-Miller S, Scott DD, Miranda VG, Mollasalehi N, Khanna M. Corrigendum: Structural Insights Into TDP-43 and Effects of Post-translational Modifications. Frontiers in Molecular Neuroscience. 13: 45. PMID 32300293 DOI: 10.3389/Fnmol.2020.00045 |
0.708 |
|
2019 |
François-Moutal L, Perez-Miller S, Scott DD, Miranda VG, Mollasalehi N, Khanna M. Structural Insights Into TDP-43 and Effects of Post-translational Modifications. Frontiers in Molecular Neuroscience. 12: 301. PMID 31920533 DOI: 10.3389/Fnmol.2019.00301 |
0.747 |
|
2019 |
Zhou Y, Cai S, Moutal A, Yu J, Gomez K, Madura CL, Shan Z, Ngan Pham NY, Serafini MJ, Dorame A, Scott DD, Francois-Moutal L, Perez-Miller S, Patek M, Khanna M, et al. The natural flavonoid Naringenin elicits analgesia through inhibition of NaV1.8 voltage-gated sodium channels. Acs Chemical Neuroscience. PMID 31697467 DOI: 10.1021/Acschemneuro.9B00547 |
0.683 |
|
2019 |
Moutal A, Shan Z, Miranda VG, François-Moutal L, Madura CL, Khanna M, Khanna R. Evaluation of edonerpic maleate as a CRMP2 inhibitor for pain relief. Channels (Austin, Tex.). 13: 498-504. PMID 31680630 DOI: 10.1080/19336950.2019.1684608 |
0.666 |
|
2019 |
Francois-Moutal L, Scott DD, Felemban R, Miranda VG, Sayegh MR, Perez-Miller S, Khanna R, Gokhale V, Zarnescu DC, Khanna M. A small molecule targeting TDP-43's RNA recognition motifs reduces locomotor defects in a Drosophila model of ALS. Acs Chemical Biology. PMID 31241884 DOI: 10.1021/Acschembio.9B00481 |
0.748 |
|
2019 |
Khanna R, Yu J, Yang X, Moutal A, Chefdeville A, Gokhale V, Shuja Z, Chew LA, Bellampalli SS, Luo S, François-Moutal L, Serafini MJ, Ha T, Perez-Miller S, Park KD, et al. Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy. Pain. PMID 30933958 DOI: 10.1097/J.Pain.0000000000001524 |
0.677 |
|
2019 |
Scott DD, Francois-Moutal L, Kumirov VK, Khanna M. H, N and C backbone assignment of apo TDP-43 RNA recognition motifs. Biomolecular Nmr Assignments. PMID 30694439 DOI: 10.1007/S12104-018-09870-X |
0.751 |
|
2018 |
Francois-Moutal L, Jahanbakhsh S, Nelson A, Ray D, Scott DD, Hennefarth M, Moutal A, Perez-Miller S, Ambrose AJ, Al-Shamari A, Coursodon P, Meechoovet B, Reiman R, Lyons E, Beilstein M, et al. A Chemical Biology Approach to Model Pontocerebellar Hypoplasia Type 1B (PCH1B). Acs Chemical Biology. PMID 30141626 DOI: 10.1021/Acschembio.8B00745 |
0.742 |
|
2018 |
François-Moutal L, Scott DD, Perez-Miller S, Gokhale V, Khanna M, Khanna R. Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels. Channels (Austin, Tex.). 1-9. PMID 30081699 DOI: 10.1080/19336950.2018.1491244 |
0.706 |
|
2018 |
François-Moutal L, Dustrude ET, Wang Y, Brustovetsky T, Dorame A, Ju W, Moutal A, Perez-Miller S, Brustovetsky N, Gokhale V, Khanna M, Khanna R. Inhibition of the Ubc9 E2 SUMO conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. Pain. PMID 29847471 DOI: 10.1097/J.Pain.0000000000001294 |
0.671 |
|
2018 |
Scott D, Kumirov V, Francois-Moutal L, Khanna M. 1H, 15N and 13C backbone assignment of apoTDP-43 RNA Recognition Motifs Journal of Back and Musculoskeletal Rehabilitation. DOI: 10.13018/Bmr27613 |
0.644 |
|
2017 |
Moutal A, Yang X, Li W, Gilbraith KB, Luo S, Cai S, François-Moutal L, Chew LA, Yeon SK, Bellampalli SS, Qu C, Xie JY, Ibrahim MM, Khanna M, Park KD, et al. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Pain. PMID 28809766 DOI: 10.1097/J.Pain.0000000000001002 |
0.656 |
|
2017 |
Dustrude ET, Perez-Miller S, François-Moutal L, Moutal A, Khanna M, Khanna R. A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function. Channels (Austin, Tex.). 0. PMID 28277940 DOI: 10.1080/19336950.2017.1299838 |
0.64 |
|
2017 |
Moutal A, Li W, Wang Y, Ju W, Luo S, Cai S, François-Moutal L, Perez-Miller S, Hu J, Dustrude ET, Vanderah TW, Gokhale V, Khanna M, Khanna R. Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of CRMP2-derived peptides. British Journal of Pharmacology. PMID 28161890 DOI: 10.1111/Bph.13737 |
0.656 |
|
2015 |
Moutal A, François-Moutal L, Perez-Miller S, Cottier K, Chew LA, Yeon SK, Dai J, Park KD, Khanna M, Khanna R. (S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5. Molecular Neurobiology. PMID 25846820 DOI: 10.1007/S12035-015-9141-2 |
0.637 |
|
2015 |
François-Moutal L, Wang Y, Moutal A, Cottier KE, Melemedjian OK, Yang X, Wang Y, Ju W, Largent-Milnes TM, Khanna M, Vanderah TW, Khanna R. A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. Pain. 156: 1247-64. PMID 25782368 DOI: 10.1097/j.pain.0000000000000147 |
0.648 |
|
2014 |
Moutal A, François-Moutal L, Brittain JM, Khanna M, Khanna R. Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides. Frontiers in Cellular Neuroscience. 8: 471. PMID 25674050 DOI: 10.3389/Fncel.2014.00471 |
0.619 |
|
2014 |
Wilson SM, Moutal A, Melemedjian OK, Wang Y, Ju W, François-Moutal L, Khanna M, Khanna R. The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth. Frontiers in Cellular Neuroscience. 8: 196. PMID 25104922 DOI: 10.3389/Fncel.2014.00196 |
0.638 |
|
Show low-probability matches. |